COMP vs EPRT

Compass, Inc. exhibits significant fundamental weakness, highlighted by a Piotroski F-Score of 3/9, placing it in the 'Weak' health category. While the company maintains strong top-line revenue growth of 23.10% and a low Price/Sales ratio of 0.84, these are offset by negative profit margins, a negative ROE of -9.79%, and a concerning liquidity position with a current ratio of 0.86. There is a stark disconnect between the bullish analyst target price of $13.25 and the internal reality of consistent earnings misses (0/4 beats in the last year) and aggressive insider selling by the CFO and General Counsel.

EPRT presents a dichotomy between strong operational performance and stretched deterministic valuations. While the Piotroski F-Score of 4/9 indicates stable financial health and the balance sheet is robust with low debt/equity (0.60), the stock trades at a significant premium to its Graham Number ($23.92) and Intrinsic Value ($8.89). Strong revenue growth (22.8%) is offset by a dangerously high dividend payout ratio (96.06%) and bearish insider activity from the CFO and CIO. Despite a 'Strong Buy' analyst consensus, the technical trend is currently bearish, suggesting a period of consolidation or correction.